Loading...
NPI 1962821355 · East Patchogue, NY · Ophthalmology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Christopher Adam is a ophthalmology physician provider located in East Patchogue, New York. This profile covers 17 Medicare and 6 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Christopher Adam |
| Address | 100 Hospital Rd Ste 216 |
| City | East Patchogue |
| State | NY |
| ZIP | 11772 |
| Taxonomy | Ophthalmology Physician |
| NPI Enumerated | April 14, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $3.1M |
| Medicaid | $219.4K |
Practice is strongly retina-focused within Ophthalmology: the top billed items are intravitreal drug administrations and retina-specific procedures and imaging, led by J0178 (injection, aflibercept), J2777 (injection, faricimab-svoa) and 67028 (vitreous chamber injection). The CPT mix — multiple high-volume injectable drug codes plus 92134 retinal imaging and procedures such as 67028 and 67042 — is consistent with a clinic that manages chronic retinal disease with frequent anti-VEGF and related intravitreal therapies.
Medicare revenue is concentrated in a narrow set of services: total Medicare revenue is $3.1M and the top 3 Medicare codes account for 82.3% of that Medicare revenue, dominated by J0178 ($1.8M, 59.9% of Medicare revenue), followed by J2777 ($511.6K, 16.7%) and 67028 ($176.7K, 5.8%). This level of concentration indicates the practice’s Medicare business is primarily driven by a few high-revenue retinal therapies and procedures.
Medicaid activity is heavily concentrated and small relative to Medicare: total Medicaid revenue is $219.4K and the top 3 Medicaid codes account for 98.6% of Medicaid revenue, led by J0178 ($182.5K, 83.1%), 67028 ($24.6K, 11.2%) and 92134 ($9.6K, 4.4%). Given Medicare $3.1M versus Medicaid $219.4K, the provider’s payer mix is effectively Medicare-dominant with Medicaid representing a small share of overall billed revenue.
Competitive standing for the largest drug code is moderate nationally: J0178 ranks #262 of 3204 providers nationally (92th percentile; typical, unremarkable volume for this code), while J2777 ranks #610 of 2039 (70th percentile; typical, unremarkable volume). These ranks indicate meaningful scale in intravitreal drug delivery but not a national dominance — the provider operates at solid, but generally typical, volumes for these injection codes.
The provider is an extreme outlier on clinical exam and retinal imaging volume: 92014 ranks #642 of 35415 providers nationally (98th percentile; extreme outlier, far above typical national volume for this code) and 92134 ranks #544 of 26868 (98th percentile; extreme outlier, far above typical national volume for this code). This suggests unusually high throughput of comprehensive established-patient exams and retinal imaging, consistent with frequent follow-up and monitoring of retinal disease cohorts.
In-state Medicaid competitiveness is modest: J0178 for Medicaid ranks #45 of 101 providers in-state (56th percentile; typical, unremarkable volume), and 67028 ranks #108 of 262 (59th percentile; typical, unremarkable volume). Those state-level positions imply the provider is an active but not dominant Medicaid participant for high-cost retinal injections within New York.
The practice’s revenue profile shows operational sensitivity to anti-VEGF utilization and reimbursement: J0178 alone accounts for $1.8M of Medicare revenue and is also the single largest Medicaid revenue driver ($182.5K). Heavy dependence on a small number of high-cost biologic injection codes means changes in drug mix, utilization patterns, or reimbursement for those codes would materially affect overall revenue.
Provider tenure is established but not long-standing relative to older practices: NPI enumerated 2014-04-14 (~12 years ago). Combined with the high volumes in both therapeutic injections and diagnostic imaging/exams, this tenure suggests a relatively mature, retina-oriented practice that has built steady referral and follow-up activity since enumeration.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
17 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 2,650 | $690 | $1.8M |
| J2777 | Injection, faricimab‑svoa, 0.1 mg | 17,640 | $30 | $511.6K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 1,580 | $110 | $176.7K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,480 | $110 | $158.3K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 2,720 | $40 | $97.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 630 | $120 | $72.8K |
| J2778 | Injection, ranibizumab, 0.1 mg | 370 | $180 | $66.6K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 400 | $160 | $63K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 320 | $80 | $25.5K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 540 | $30 | $17.8K |
Showing 1–10 of 17
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
17 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J0178 | 21 | 230 | 560 | $690 | $693K |
| J2777 | 24 | 120 | 7,740 | $30 | $364.9K |
| J2778 | 50 | 70 | 510 | $180 | $131.6K |
| 67028 | 35 | 300 | 400 | $100 | $65.9K |
| J7312 | 4 | 20 | 270 | $160 | $48K |
| 67210 | 38 | 40 | 40 | $430 | $46.9K |
| 92014 | 58 | 2,220 | 160 | $100 | $29.3K |
| 67042 | 31 | 40 | 20 | $1,030 | $22.7K |
| 99214 | 1,961 | 30,450 | 90 | $100 | $19K |
| 92235 | 114 | 190 | 60 | $120 | $14.1K |
Showing 1–10 of 17
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
6 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 350 | $520 | $182.5K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 670 | $40 | $24.6K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 960 | $10 | $9.6K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 100 | $20 | $1.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 40 | $20 | $680 |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 30 | $30 | $650 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
6 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 45 | 100 | 280 | $650 | $369.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 12,783 | 16,550 | 220 | $90 | $186.8K |
| 92014 | An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group… | 1,684 | 2,440 | 330 | $70 | $92.6K |
| 67028 | The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye. | 108 | 260 | 420 | $70 | $65.6K |
| 92250 | Code 92250 describes the taking of fundus photographs, that is, photographs of the posterior segment of the inner aspect of the eye, to document alterations in the optic nerve head, retinal vessels,… | 1,293 | 1,490 | 340 | $40 | $48.7K |
| 92134 | The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes. | 236 | 730 | 370 | $20 | $30K |
Other providers in the same ZIP code as Christopher Adam, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Sarene Services Inc | NY | Nursing Care Agency | $0 | $63M |
| Long Island Community Hospital At Nyu Langone Health | NY | General Acute Care Hospital | $0 | $27.6M |
| Great South Bay Endoscopy Center, LLC | NY | Ambulatory Surgical Clinic/Center | $912.1K | $3.5M |
| Aleksander Vayntraub | NY | Radiation Oncology Physician | $2.1M | $700 |
| Shahid Nawaz | NY | Hematology & Oncology Physician | $2M | $85.7K |
| Ravi Pulipati | NY | Vascular Surgery Physician | $2M | $24.6K |
| Sanjeev Jain | NY | Hematology & Oncology Physician | $1.5M | $59.6K |
| Adeel Iqbal | NY | Internal Medicine Physician | $1.3M | $10.1K |
| Hitesh Narain | NY | Obstetrics & Gynecology Physician | $22.4K | $1M |
| Raja Varma | NY | Cardiovascular Disease Physician | $885.3K | $5.4K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.